Mereo BioPharma Reports First Quarter 2025 Financial Results and Provides Corporate Highlights
Provided By GlobeNewswire
Last update: May 13, 2025
Progress continues in Phase 3 Orbit study of setrusumab in osteogenesis imperfecta (OI)
Cash of $62.5 million as of March 31, 2025, expected to fund operations into 2027
Read more at globenewswire.comNASDAQ:MREO (8/25/2025, 1:00:34 PM)
1.785
+0.08 (+5%)
Find more stocks in the Stock Screener
